AR125142A1 - Moléculas de unión terapéuticas - Google Patents
Moléculas de unión terapéuticasInfo
- Publication number
- AR125142A1 AR125142A1 ARP220100634A ARP220100634A AR125142A1 AR 125142 A1 AR125142 A1 AR 125142A1 AR P220100634 A ARP220100634 A AR P220100634A AR P220100634 A ARP220100634 A AR P220100634A AR 125142 A1 AR125142 A1 AR 125142A1
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- amino acid
- ccr9
- acid sequence
- region comprises
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 7
- 102100036303 C-C chemokine receptor type 9 Human genes 0.000 abstract 4
- 101000678892 Homo sapiens Atypical chemokine receptor 2 Proteins 0.000 abstract 4
- 101000716070 Homo sapiens C-C chemokine receptor type 9 Proteins 0.000 abstract 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 2
- 102100021933 C-C motif chemokine 25 Human genes 0.000 abstract 1
- 102000004900 CC chemokine receptor 9 Human genes 0.000 abstract 1
- 108090001026 CC chemokine receptor 9 Proteins 0.000 abstract 1
- 101000897486 Homo sapiens C-C motif chemokine 25 Proteins 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
La invención se refiere a moléculas de unión, tales como anticuerpos, que se unen al receptor de quimiocinas CCR9. Más particularmente, la invención se refiere al tratamiento de enfermedades o afecciones mediadas por CCR9, tales como la enfermedad Inflamatoria Intestinal (EII), y a métodos que, para la detección de CCR9, utilizan las moléculas de unión de la invención. Reivindicación 1: Una molécula de unión que se une a CCR9 y que comprende una región variable de cadena pesada (VH) que tiene un conjunto de CDR HCDR1, HCDR2 y HCDR3, y una región variable de cadena ligera (VL) que tiene un conjunto de CDR LCDR1, LCDR2 y LCDR3, en donde (a) la secuencia de aminoácidos de la región VH comprende HCDR1 de SEQ ID Nº 1, HCDR2 de SEQ ID Nº 2 y HCDR3 de SEQ ID Nº 3, y en donde la secuencia de aminoácidos de la región VL comprende LCDR1 de SEQ ID Nº 4, LCDR2 de SEQ ID Nº 5 y LCDR3 de SEQ ID Nº 6; (b) la secuencia de aminoácidos de la región VH comprende HCDR1 de SEQ ID Nº 7, HCDR2 de SEQ ID Nº 8 y HCDR3 de SEQ ID Nº 9, y en donde la secuencia de aminoácidos de la región VL comprende LCDR1 de SEQ ID Nº 10, LCDR2 de SEQ ID Nº 11 y LCDR3 de SEQ ID Nº 12; o (c) la secuencia de aminoácidos de la región VH comprende HCDR1 de SEQ ID Nº 13, HCDR2 de SEQ ID Nº 14 y HCDR3 de SEQ ID Nº 15, y en donde la secuencia de aminoácidos de la región VL comprende LCDR1 de SEQ ID Nº 16, LCDR2 de SEQ ID Nº 17 y LCDR3 de SEQ ID Nº 18 o en donde una cualquiera o más de dichas HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 y LCDR3 comprenden 1, 2 ó 3 sustituciones de aminoácidos en comparación con dichas secuencias. Reivindicación 19: Un agente terapéutico que comprende un anticuerpo anti-CCR9 como principio activo, en donde el anticuerpo anti-CCR9 compite con CCL25 por unirse a CCR9 humano.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163162603P | 2021-03-18 | 2021-03-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR125142A1 true AR125142A1 (es) | 2023-06-14 |
Family
ID=81327268
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP220100634A AR125142A1 (es) | 2021-03-18 | 2022-03-18 | Moléculas de unión terapéuticas |
Country Status (16)
Country | Link |
---|---|
US (1) | US20220306754A1 (es) |
EP (1) | EP4308607A2 (es) |
JP (1) | JP2024516769A (es) |
KR (1) | KR20230158526A (es) |
CN (1) | CN116997571A (es) |
AR (1) | AR125142A1 (es) |
AU (1) | AU2022236492A1 (es) |
BR (1) | BR112023018331A2 (es) |
CA (1) | CA3212630A1 (es) |
CL (1) | CL2023002759A1 (es) |
CO (1) | CO2023013566A2 (es) |
CR (1) | CR20230488A (es) |
EC (1) | ECSP23078844A (es) |
IL (1) | IL305690A (es) |
TW (1) | TW202304985A (es) |
WO (1) | WO2022195028A2 (es) |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2183661B (en) | 1985-03-30 | 1989-06-28 | Marc Ballivet | Method for obtaining dna, rna, peptides, polypeptides or proteins by means of a dna recombinant technique |
US6492107B1 (en) | 1986-11-20 | 2002-12-10 | Stuart Kauffman | Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique |
US5618920A (en) | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
DE3600905A1 (de) | 1986-01-15 | 1987-07-16 | Ant Nachrichtentech | Verfahren zum dekodieren von binaersignalen sowie viterbi-dekoder und anwendungen |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
CA2016842A1 (en) | 1989-05-16 | 1990-11-16 | Richard A. Lerner | Method for tapping the immunological repertoire |
AU652539B2 (en) | 1989-05-16 | 1994-09-01 | Medical Research Council | Co-expression of heteromeric receptors |
CA2016841C (en) | 1989-05-16 | 1999-09-21 | William D. Huse | A method for producing polymers having a preselected activity |
US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
IL99552A0 (en) | 1990-09-28 | 1992-08-18 | Ixsys Inc | Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof |
ES2113940T3 (es) | 1990-12-03 | 1998-05-16 | Genentech Inc | Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas. |
DE69233745D1 (de) | 1991-12-02 | 2008-10-23 | Cambridge Antibody Tech | Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken |
ES2202310T3 (es) | 1991-12-13 | 2004-04-01 | Xoma Corporation | Metodos y materiales para la preparacion de dominios variables de anticuerpos modificados y sus usos terapeuticos. |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
US6706484B1 (en) | 1995-08-18 | 2004-03-16 | Morphosys Ag | Protein/(poly)peptide libraries |
ES2176484T3 (es) | 1995-08-18 | 2002-12-01 | Morphosys Ag | Bancos de proteinas/(poli)peptidos. |
US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
DK2180007T4 (da) | 1998-04-20 | 2017-11-27 | Roche Glycart Ag | Glycosyleringsteknik for antistoffer til forbedring af antistofafhængig cellecytotoxicitet |
DK2270147T4 (da) | 1999-04-09 | 2020-08-31 | Kyowa Kirin Co Ltd | Fremgangsmåde til at kontrollere aktiviteten af immunologisk funktionelt molekyle |
DE60044997D1 (de) | 1999-07-02 | 2010-11-04 | Morphosys Ag | Erzeugung spezifischer bindungspartner die an von genomischen dns-fragmenten oder ests kodierten (poly)peptiden binden |
CN100423777C (zh) | 2001-10-25 | 2008-10-08 | 杰南技术公司 | 糖蛋白组合物 |
US7538195B2 (en) | 2002-06-14 | 2009-05-26 | Immunogen Inc. | Anti-IGF-I receptor antibody |
NZ539395A (en) | 2002-11-07 | 2009-01-31 | Immunogen Inc | Anti-CD33 antibodies and method for treatment of acute myeloid leukemia using the same |
GB0624500D0 (en) * | 2006-12-07 | 2007-01-17 | Istituto Superiore Di Sanito | A novel passive vaccine for candida infections |
JP5470817B2 (ja) | 2008-03-10 | 2014-04-16 | 日産自動車株式会社 | 電池用電極およびこれを用いた電池、並びにその製造方法 |
PL2480671T3 (pl) | 2009-09-22 | 2015-12-31 | Probiogen Ag | Proces produkcji cząsteczek zawierających specjalne struktury glikanowe |
JP6136279B2 (ja) | 2013-01-15 | 2017-05-31 | 株式会社ジェイテクト | 転がり軸受装置 |
TWI503850B (zh) | 2013-03-22 | 2015-10-11 | Polytronics Technology Corp | 過電流保護元件 |
TWI510996B (zh) | 2013-10-03 | 2015-12-01 | Acer Inc | 控制觸控面板的方法以及使用該方法的可攜式電腦 |
EP2876114A1 (en) * | 2013-11-25 | 2015-05-27 | Consejo Superior De Investigaciones Científicas | Antibodies against CCR9 and applications thereof |
CA2874083C (en) * | 2014-12-05 | 2024-01-02 | Universite Laval | Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases |
US9816280B1 (en) | 2016-11-02 | 2017-11-14 | Matthew Reitnauer | Portable floor |
-
2022
- 2022-03-17 EP EP22716861.4A patent/EP4308607A2/en active Pending
- 2022-03-17 BR BR112023018331A patent/BR112023018331A2/pt unknown
- 2022-03-17 US US17/697,041 patent/US20220306754A1/en active Pending
- 2022-03-17 IL IL305690A patent/IL305690A/en unknown
- 2022-03-17 CR CR20230488A patent/CR20230488A/es unknown
- 2022-03-17 KR KR1020237034201A patent/KR20230158526A/ko unknown
- 2022-03-17 CA CA3212630A patent/CA3212630A1/en active Pending
- 2022-03-17 CN CN202280021611.7A patent/CN116997571A/zh active Pending
- 2022-03-17 AU AU2022236492A patent/AU2022236492A1/en active Pending
- 2022-03-17 WO PCT/EP2022/057029 patent/WO2022195028A2/en active Application Filing
- 2022-03-17 JP JP2023556501A patent/JP2024516769A/ja active Pending
- 2022-03-18 AR ARP220100634A patent/AR125142A1/es unknown
- 2022-03-18 TW TW111110226A patent/TW202304985A/zh unknown
-
2023
- 2023-09-15 CL CL2023002759A patent/CL2023002759A1/es unknown
- 2023-10-13 CO CONC2023/0013566A patent/CO2023013566A2/es unknown
- 2023-10-17 EC ECSENADI202378844A patent/ECSP23078844A/es unknown
Also Published As
Publication number | Publication date |
---|---|
JP2024516769A (ja) | 2024-04-17 |
CR20230488A (es) | 2023-12-12 |
AU2022236492A1 (en) | 2023-10-26 |
TW202304985A (zh) | 2023-02-01 |
ECSP23078844A (es) | 2023-11-30 |
IL305690A (en) | 2023-11-01 |
EP4308607A2 (en) | 2024-01-24 |
CN116997571A (zh) | 2023-11-03 |
US20220306754A1 (en) | 2022-09-29 |
WO2022195028A3 (en) | 2022-10-27 |
KR20230158526A (ko) | 2023-11-20 |
BR112023018331A2 (pt) | 2023-12-12 |
CO2023013566A2 (es) | 2023-10-30 |
AU2022236492A9 (en) | 2023-11-09 |
CL2023002759A1 (es) | 2024-02-16 |
WO2022195028A2 (en) | 2022-09-22 |
CA3212630A1 (en) | 2022-09-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR126019A1 (es) | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación | |
PE20211767A1 (es) | Anticuerpos anti-hla-g, composiciones que comprenden anticuerpos anti-hla-g y metodos de uso de anticuerpos anti-hla-g | |
PE20200294A1 (es) | Anticuerpos que se unen especificamente a pd-1 y metodos de uso | |
AR110719A1 (es) | Anticuerpos humanos a la toxina hemolisina a de s. aureus | |
AR052959A1 (es) | Anticuerpos anti- ccr5 y usos de los mismos | |
JP2017535257A5 (es) | ||
RU2014109039A (ru) | Биспецифические антигенсвязывающие молекулы | |
RU2014148502A (ru) | Человеческие антитела к fel d1 и способы их применения | |
RU2010141584A (ru) | Антитело против csf-1r | |
JP2013542194A5 (es) | ||
NZ625403A (en) | Composition and method for diagnosis and treatment of diseases associated with neurite degeneration | |
CO6230999A2 (es) | Anticuerpo anti-esclerostina | |
RU2016100892A (ru) | Антитела против tweakr и их применение | |
PE20191079A1 (es) | Inmunoglobulinas y usos de estas | |
RU2018102606A (ru) | Молекулы, связывающиеся с psl pseudomonas, и пути их применения | |
RU2010126078A (ru) | Антитело против nr10 и его применение | |
JP2015513903A5 (es) | ||
RU2017114968A (ru) | Связывающие молекулы, а именно антитела, способные связываться с l1cam (cd171) | |
JP2024024114A5 (es) | ||
AR098663A1 (es) | Anticuerpos multifuncionales que se unen a egfr y met | |
PE20220575A1 (es) | Anticuerpos multiespecificos de cadena pesada que se unen a cd22 y cd3 | |
PE20201255A1 (es) | Anticuerpos y conjugados de anticuerpo-farmaco especificos para cd123 y usos de los mismos | |
AR110967A1 (es) | Anticuerpos miméticos fgf21 y su uso | |
RU2017104638A (ru) | Нейтрализующие антитела к вирусу гриппа B и пути их применения | |
AR104906A1 (es) | Anticuerpos dirigidos a la proteína morfogenética ósea 9 (bmp9) y métodos a partir de estos |